Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM.

Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468.

2.

Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651. [Epub ahead of print] No abstract available.

PMID:
31591736
3.

How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia.

Frisch A, Ofran Y.

Haematologica. 2019 Nov;104(11):2135-2143. doi: 10.3324/haematol.2018.207506. Epub 2019 Oct 3. Review.

4.

Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis.

Beyar-Katz O, Bitterman R, Zuckerman T, Ofran Y, Yahav D, Paul M.

Clin Microbiol Infect. 2019 Sep 16. pii: S1198-743X(19)30488-4. doi: 10.1016/j.cmi.2019.09.003. [Epub ahead of print] Review.

PMID:
31536817
5.

Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.

Berger T, Rozovski U, Moshe Y, Yaari S, Frisch A, Hellmann I, Apel A, Aviram A, Koren-Michowitz M, Yeshurun M, Ram R, Raanani P, Ofran Y, Wolach O.

Ann Hematol. 2019 Dec;98(12):2711-2717. doi: 10.1007/s00277-019-03795-8. Epub 2019 Sep 11.

PMID:
31512015
6.

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.

Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D, Henig I, Beyar-Katz O, Hayun M, Frisch A.

Leukemia. 2019 Aug 21. doi: 10.1038/s41375-019-0548-z. [Epub ahead of print] No abstract available.

PMID:
31435023
7.

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

Beyar-Katz O, Lavi N, Ringelstein-Harlev S, Henig I, Yehudai-Ofir D, Haddad N, Fineman R, Ofran Y, Nov Y, Sahar D, Moustafa-Hawash N, Rowe JM, Zuckerman T.

Leuk Lymphoma. 2019 Oct;60(10):2449-2456. doi: 10.1080/10428194.2019.1594214. Epub 2019 Apr 3.

PMID:
30943060
8.

The role of specialized hospital units in infection and mortality risk reduction among patients with hematological cancers.

Carmen R, Yom-Tov GB, Van Nieuwenhuyse I, Foubert B, Ofran Y.

PLoS One. 2019 Mar 20;14(3):e0211694. doi: 10.1371/journal.pone.0211694. eCollection 2019.

9.

Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype.

Paperna T, Sharon-Shwartzman N, Kurolap A, Goldberg Y, Moustafa N, Carasso Y, Feinstien M, Mory A, Reznick-Levi G, Gonzaga-Jauregui C, Shuldiner AR, Basel-Salmon L, Ofran Y, Half EE, Baris Feldman H.

J Med Genet. 2019 Mar 11. pii: jmedgenet-2018-105824. doi: 10.1136/jmedgenet-2018-105824. [Epub ahead of print]

PMID:
30858171
10.

Baseline Chest Computed Tomography for Early Diagnosis of Invasive Pulmonary Aspergillosis in Hemato-oncological Patients: A Prospective Cohort Study.

Bitterman R, Hardak E, Raines M, Stern A, Zuckerman T, Ofran Y, Lavi N, Guralnik L, Frisch A, Nudelman O, Paul M, Oren I.

Clin Infect Dis. 2019 Oct 30;69(10):1805-1808. doi: 10.1093/cid/ciz194.

PMID:
30855077
11.

Palliative care service incorporated in a hematology department: a working model fostering changes in clinical practice.

Ofran Y, Bar-Sela G, Toledano M, Kushnir I, Moalem B, Gil W, Kazman N, Fineman R.

Leuk Lymphoma. 2019 Aug;60(8):2079-2081. doi: 10.1080/10428194.2018.1564826. Epub 2019 Jan 25. No abstract available.

PMID:
30681028
12.

Computational Design of Epitope-Specific Functional Antibodies.

Nimrod G, Fischman S, Austin M, Herman A, Keyes F, Leiderman O, Hargreaves D, Strajbl M, Breed J, Klompus S, Minton K, Spooner J, Buchanan A, Vaughan TJ, Ofran Y.

Cell Rep. 2018 Nov 20;25(8):2121-2131.e5. doi: 10.1016/j.celrep.2018.10.081.

13.

Computational design of antibodies.

Fischman S, Ofran Y.

Curr Opin Struct Biol. 2018 Aug;51:156-162. doi: 10.1016/j.sbi.2018.04.007. Epub 2018 May 20. Review.

PMID:
29791878
14.

Characteristics of ataxic gait in familial dysautonomia patients.

Portnoy S, Maayan C, Tsenter J, Ofran Y, Goldman V, Hiller N, Karniel N, Schwartz I.

PLoS One. 2018 Apr 26;13(4):e0196599. doi: 10.1371/journal.pone.0196599. eCollection 2018.

15.
16.

A novel Fer/FerT targeting compound selectively evokes metabolic stress and necrotic death in malignant cells.

Elkis Y, Cohen M, Yaffe E, Satmary-Tusk S, Feldman T, Hikri E, Nyska A, Feiglin A, Ofran Y, Shpungin S, Nir U.

Nat Commun. 2017 Oct 16;8(1):940. doi: 10.1038/s41467-017-00832-w.

17.

Grb2 regulates the proliferation of hematopoietic stem and progenitors cells.

Frelin C, Ofran Y, Ruston J, Hayun M, Derdikman Y, Khier Y, Rozales K, Brenner B, Iscove N, Pawson T, Louria-Hayon I.

Biochim Biophys Acta Mol Cell Res. 2017 Dec;1864(12):2449-2459. doi: 10.1016/j.bbamcr.2017.09.018. Epub 2017 Sep 28.

18.

Activated kinases in ALL: time to act.

Ofran Y.

Blood. 2017 Jun 22;129(25):3280-3282. doi: 10.1182/blood-2017-05-780015. No abstract available.

PMID:
28642359
19.

Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges.

Daneshjou R, Wang Y, Bromberg Y, Bovo S, Martelli PL, Babbi G, Lena PD, Casadio R, Edwards M, Gifford D, Jones DT, Sundaram L, Bhat RR, Li X, Pal LR, Kundu K, Yin Y, Moult J, Jiang Y, Pejaver V, Pagel KA, Li B, Mooney SD, Radivojac P, Shah S, Carraro M, Gasparini A, Leonardi E, Giollo M, Ferrari C, Tosatto SCE, Bachar E, Azaria JR, Ofran Y, Unger R, Niroula A, Vihinen M, Chang B, Wang MH, Franke A, Petersen BS, Pirooznia M, Zandi P, McCombie R, Potash JB, Altman RB, Klein TE, Hoskins RA, Repo S, Brenner SE, Morgan AA.

Hum Mutat. 2017 Sep;38(9):1182-1192. doi: 10.1002/humu.23280. Epub 2017 Jul 7.

20.

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Litzow MR, Fielding AK, Luger SM, Paietta E, Ofran Y, Rowe JM, Goldstone AH, Tallman MS, Lazarus HM.

Bone Marrow Transplant. 2017 Dec;52(12):1592-1598. doi: 10.1038/bmt.2017.110. Epub 2017 Jun 5. Review.

PMID:
28581459

Supplemental Content

Support Center